$IMNM

$18.77 +$0.88 (4.92%) Close

$IMNM Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Company Executives

$IMNM Management Team

Dr. Phil Tsai

Chief Technical Officer

Age 57

Compensation -

Sex Male

Mr. Kinney Horn

Chief Business Officer

Age 50

Compensation $6.990M USD

Sex Male

Dr. Clay Siegall

Chairman of the Board

President

Chief Executive Officer

Age 64

Compensation $9.227M USD

Sex Male

Mr. Max Rosett

Chief Financial Officer

Age 35

Compensation -

Sex Male

Dr. Jack Higgins

Chief Scientific Officer

Age 46

Compensation $1.841M USD

Sex Male

Ms. Sandra Stoneman

Chief Legal Officer

General Counsel

Corporate Secretary

Age 52

Compensation $5.247M USD

Sex Female

Dr. Bob Lechleider

Chief Medical Officer

Age 64

Compensation $2.915M USD

Sex Male

Name / Title	Age	Compensation	Sex
Dr. Phil Tsai Chief Technical Officer	57	-	Male
Mr. Kinney Horn Chief Business Officer	50	$6.990M USD	Male
Dr. Clay Siegall Chairman of the Board President Chief Executive Officer	64	$9.227M USD	Male
Mr. Max Rosett Chief Financial Officer	35	-	Male
Dr. Jack Higgins Chief Scientific Officer	46	$1.841M USD	Male
Ms. Sandra Stoneman Chief Legal Officer General Counsel Corporate Secretary	52	$5.247M USD	Female
Dr. Bob Lechleider Chief Medical Officer	64	$2.915M USD	Male

Board of Directors

From the proxy statement filed Apr 24, 2026

Directors

serving now

Independent

6 of 6

stated in the proxy; 1 not stated

Average tenure

3.6 years

from year joined

CEO also chairs the board

Yes

Clay Siegall, Ph.D.

Director	Age	On board	Independent	Committees	Other public boards	2025 pay
James Boylan	59	2023 3 years	Independent	Compensation · Chair	Compass Therapeutics, Inc. (NASDAQ: CMPX)	$190,000
Philip Wagenheim	55	2017 9 years	Independent	None stated	Swarmer Inc. (NASDAQ: SWMR)	$175,000
Sandra Swain, M.D.	72	2024 2 years	Independent	Audit Committee	None stated	$182,500
Clay Siegall, Ph.D. Board chair, CEO	65	2023 3 years	Not stated	None stated	Shattuck Labs, Inc. (Nasdaq: STTK)	Paid as CEO
Carol Schafer	62	2024 2 years	Independent	Audit · Chair	Insmed Incorporated (NASDAQ: INSM), Kura Oncology, Inc. (NASDAQ: KURA)	$195,000
Isaac Barchas Lead independent director	58	2023 3 years	Independent	Nominating and Corporate Governance · Chair	None stated	$210,000
Jean-Jacques Bienaimé	72	2023 3 years	Independent	Audit Compensation	Incyte Corporation (NASDAQ: INCY)	$187,500

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

3 disclosed in the proxy filed Apr 24, 2026

Clay Siegall, Ph.D.

President, CEO and Chairman of the Board

$1.0 million

Purchased 46,511 shares of common stock in the December 2025 underwritten public offering

Open in proxy

Clay Siegall, Ph.D.

President, CEO and Chairman of the Board

$1.2 million

Purchased 150,000 shares of common stock in the January 2025 underwritten public offering

Open in proxy

Immunome Aggregator, L.P.

Former 5% Stockholder

$10.0 million

Purchased 1,290,322 shares of common stock in the January 2025 underwritten public offering

Open in proxy

Comments

Company Executives

$IMNM Management Team

Dr. Phil Tsai

Mr. Kinney Horn

Dr. Clay Siegall

Mr. Max Rosett

Dr. Jack Higgins

Ms. Sandra Stoneman

Dr. Bob Lechleider

Board of Directors

Related-party transactions